| $687M | ||
| $385M | ||
| $215M | ||
| $100M | ||
| $94M | ||
| $82M |
Buys | $26,099,165 | 4 | 21 |
Sells | $276,130 | 15 | 79 |
| PERCEPTIVE ADVISORS LLC | 1 | $20.15M | 0 | $0 | $20.15M | |
| Bain Capital Life Sciences Investors, LLC | 10 percent owner | 1 | $4.03M | 0 | $0 | $4.03M |
| Adage Capital Management, L.P. | 10 percent owner | 1 | $1.91M | 0 | $0 | $1.91M |
| Kahn Clare | director | 1 | $9,924 | 0 | $0 | $9,924 |
| Tan Kevin | CFO & Treasurer | 0 | $0 | 1 | $12,529 | $-12,529 |
| Herzich Paul | Chief Technology Officer | 0 | $0 | 2 | $24,447 | $-24,447 |
| Ganot Ilan | director | 0 | $0 | 4 | $26,446 | $-26,446 |
| Brooks Gabriel | Chief Medical Officer | 0 | $0 | 2 | $30,148 | $-30,148 |
| Hanrahan Jessie | Chief Regulatory Officer | 0 | $0 | 2 | $35,101 | $-35,101 |
| Howton David T | Chief Operating Officer | 0 | $0 | 2 | $47,224 | $-47,224 |
| Cumbo Alexander | President and CEO | 0 | $0 | 2 | $100,234 | $-100,234 |
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Over the last 12 months, insiders at Solid Biosciences Inc. have bought $26.1M and sold $276,130 worth of Solid Biosciences Inc. stock.
On average, over the past 5 years, insiders at Solid Biosciences Inc. have bought $26.34M and sold $301,597 worth of stock each year.
Highest buying activity among insiders over the last 12 months: PERCEPTIVE ADVISORS LLC () — $20.15M. Bain Capital Life Sciences Investors, LLC (10 percent owner) — $4.03M. Adage Capital Management, L.P. (10 percent owner) — $1.91M.
The last purchase of 1,860 shares for transaction amount of $9,924 was made by Kahn Clare (director) on 2025‑03‑11.
| 2026-01-05 | Sale | Ganot Ilan | director | 1,053 0.0014% | $5.43 | $5,718 | +1.87% | |
| 2025-12-03 | Sale | Cumbo Alexander | President and CEO | 10,808 0.0137% | $5.11 | $55,229 | +9.74% | |
| 2025-12-03 | Sale | Howton David T | Chief Operating Officer | 4,932 0.0062% | $5.11 | $25,203 | +9.74% | |
| 2025-12-03 | Sale | Hanrahan Jessie | Chief Regulatory Officer | 4,483 0.0057% | $5.11 | $22,908 | +9.74% | |
| 2025-12-03 | Sale | Herzich Paul | Chief Technology Officer | 2,701 0.0034% | $5.11 | $13,802 | +9.74% | |
| 2025-11-10 | Sale | Ganot Ilan | director | 3,278 0.0043% | $4.12 | $13,505 | +32.47% | |
| 2025-10-20 | Sale | Brooks Gabriel | Chief Medical Officer | 2,895 0.0036% | $5.96 | $17,254 | -11.38% | |
| 2025-03-11 | Kahn Clare | director | 1,860 0.0023% | $5.34 | $9,924 | -6.19% | ||
| 2025-02-19 | PERCEPTIVE ADVISORS LLC | 5M 9.5155% | $4.03 | $20.15M | -17.93% | |||
| 2025-02-19 | Bain Capital Life Sciences Investors, LLC | 10 percent owner | 1M 1.9031% | $4.03 | $4.03M | -17.93% | ||
| 2025-02-18 | Adage Capital Management, L.P. | 10 percent owner | 252,545 1.1857% | $7.56 | $1.91M | +0.19% | ||
| 2025-02-14 | Sale | Cumbo Alexander | President and CEO | 11,365 0.0286% | $3.96 | $45,005 | +31.76% | |
| 2025-02-14 | Sale | Tan Kevin | CFO & Treasurer | 3,164 0.008% | $3.96 | $12,529 | +31.76% | |
| 2025-02-14 | Sale | Howton David T | Chief Operating Officer | 5,561 0.014% | $3.96 | $22,022 | +31.76% | |
| 2025-02-14 | Sale | Brooks Gabriel | Chief Medical Officer | 3,256 0.0082% | $3.96 | $12,894 | +31.76% | |
| 2025-02-14 | Sale | Hanrahan Jessie | Chief Regulatory Officer | 3,079 0.0077% | $3.96 | $12,193 | +31.76% | |
| 2025-02-14 | Sale | Herzich Paul | Chief Technology Officer | 2,688 0.0068% | $3.96 | $10,644 | +31.76% | |
| 2025-02-14 | Sale | Ganot Ilan | director | 1,711 0.0043% | $3.96 | $6,776 | +31.76% | |
| 2025-01-28 | Sale | Ganot Ilan | director | 144 0.0003% | $3.11 | $448 | +60.37% | |
| 2025-01-10 | Sale | Tan Kevin | CFO & Treasurer | 4,073 0.0109% | $3.89 | $15,849 | +40.56% |
| PERCEPTIVE ADVISORS LLC | 11833539 15.1889% | $62.6M | 5 | 0 | <0.0001% | |
| Bain Capital Life Sciences Investors, LLC | 10 percent owner | 5034582 6.4621% | $26.63M | 1 | 0 | |
| Adage Capital Management, L.P. | 10 percent owner | 4248084 5.4526% | $22.47M | 1 | 0 | |
| Cumbo Alexander | President and CEO | 81388 0.1045% | $430,542.52 | 0 | 4 | |
| Brooks Gabriel | Chief Medical Officer | 33819 0.0434% | $178,902.51 | 0 | 3 | |
| Howton David T | Chief Operating Officer | 32908 0.0422% | $174,083.32 | 0 | 4 | |
| Tan Kevin | CFO & Treasurer | 32250 0.0414% | $170,602.50 | 0 | 3 | |
| Hanrahan Jessie | Chief Regulatory Officer | 26660 0.0342% | $141,031.40 | 0 | 4 | |
| Herzich Paul | Chief Technology Officer | 26622 0.0342% | $140,830.38 | 0 | 4 | |
| Ganot Ilan | director | 17278 0.0222% | $91,400.62 | 0 | 16 | |
| Kahn Clare | director | 2960 0.0038% | $15,658.40 | 2 | 0 | <0.0001% |
| RA CAPITAL MANAGEMENT, L.P. | 4192216 5.3809% | $22.18M | 2 | 0 | <0.0001% | |
| Boxer Capital, LLC | 10 percent owner | 3473272 4.4581% | $18.37M | 0 | 3 | |
| Arnold Matthew Bennett | director | 3386293 4.3465% | $17.91M | 0 | 2 | |
| Shah Rajeev M. | director | 2689444 3.452% | $14.23M | 1 | 0 | |
| Koppel Adam | director | 1989444 2.5536% | $10.52M | 1 | 0 | |
| Ziolkowski Jennifer Lynn | CFO, Treasurer & Asst. Secy | 335636 0.4308% | $1.78M | 0 | 2 | |
| Schneider Joel Solomon Zev | Chief Operating Officer | 251542 0.3229% | $1.33M | 0 | 5 | |
| Quiroz Jorge Armando | Chief Medical Officer | 228092 0.2928% | $1.21M | 0 | 2 | |
| HERSCHA LYNETTE | Chief Legal Officer | 160859 0.2065% | $850,944.11 | 0 | 1 | |
| Amorrortu Pedro Alvaro | Chief Operating Officer | 153746 0.1973% | $813,316.34 | 0 | 3 | |
| Morris Carl Ashley | Chief Scientific Officer | 19760 0.0254% | $104,530.40 | 0 | 5 | |
| Zarur Juan Andrey | director | 10189 0.0131% | $53,899.81 | 0 | 2 | |
| Marlowe Jennifer | CSO | 6998 0.009% | $37,019.42 | 0 | 1 |
$860,541,348 | 82 | -5.10% | $425.18M | |
$54,836,085 | 68 | -0.52% | $393.36M | |
$17,468,215 | 46 | 18.85% | $424.95M | |
$130,095 | 43 | 45.19% | $382.41M | |
$63,049,419 | 31 | 2.87% | $370.77M | |
$74,231,875 | 30 | 40.62% | $382.96M | |
$54,828,550 | 26 | -13.88% | $403.36M | |
$4,306,464 | 21 | 37.34% | $414.6M | |
$104,137,421 | 15 | 21.28% | $403.67M | |
$8,069,667 | 13 | -13.57% | $451.03M | |
$112,952,085 | 11 | -19.19% | $460.08M | |
$57,263,116 | 11 | -8.37% | $384.29M | |
$14,995,689 | 8 | 3.76% | $433.15M | |
$166,385 | 7 | -23.62% | $403.35M | |
$43,326,461 | 6 | 16.01% | $444.73M | |
$12,035,408 | 5 | -37.54% | $421M | |
Solid Biosciences Inc. (SLDB) | $79,246,559 | 5 | -27.73% | $412.14M |
$58,352 | 4 | -43.78% | $406.91M | |
$2,857,000 | 2 | -5.23% | $423.48M |
| Increased Positions | 65 | +52.85% | 7M | +8.13% |
| Decreased Positions | 49 | -39.84% | 8M | -9.22% |
| New Positions | 25 | New | 3M | New |
| Sold Out Positions | 11 | Sold Out | 3M | Sold Out |
| Total Postitions | 139 | +13.01% | 82M | -1.08% |
| Perceptive Advisors Llc | $64,493.00 | 15.17% | 11.83M | -73,107 | -0.61% | 2025-09-30 |
| Bain Capital Life Sciences Investors, Llc | $43,119.00 | 10.14% | 7.91M | 0 | 0% | 2025-09-30 |
| Siren, L.L.C. | $40,417.00 | 9.51% | 7.42M | 0 | 0% | 2025-09-30 |
| Ra Capital Management, L.P. | $31,672.00 | 7.45% | 5.81M | +100 | +<0.01% | 2025-09-30 |
| Blackrock, Inc. | $25,752.00 | 6.06% | 4.73M | -194,965 | -3.96% | 2025-09-30 |
| Adage Capital Partners Gp, L.L.C. | $21,800.00 | 5.13% | 4M | -3M | -40.56% | 2025-09-30 |
| Vanguard Group Inc | $16,807.00 | 3.95% | 3.08M | -281,697 | -8.37% | 2025-09-30 |
| Vestal Point Capital, Lp | $16,214.00 | 3.81% | 2.98M | +1M | +97.67% | 2025-09-30 |
| Fmr Llc | $15,882.00 | 3.74% | 2.91M | -264,273 | -8.31% | 2025-09-30 |
| Citadel Advisors Llc | $14,130.00 | 3.32% | 2.59M | +69,404 | +2.75% | 2025-09-30 |